Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — December 2024

Genmab — December 2024

Planlagt Fastgjort Låst Flyttet Genmab
476 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #10

    maybe it is coincidence, but it seems JP Morgen needs to stay within a ~10% range of the current price with their targets since they started downgrading:

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #11

      may23, target 3200 market 2880 =~11%,
      dec23, target 2500 market 2200 =~14%,
      aug24 target 2050 market 1850 =~11%,
      dec24 target 1700 market 1551 =~10%,

      1 Reply Last reply
      0
      • R Offline
        R Offline
        Riis7
        wrote on sidst redigeret af
        #12

        Maybe AI is making it;-)

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #13

          😉

          1 Reply Last reply
          0
          • J Offline
            J Offline
            JKY_VH
            wrote on sidst redigeret af
            #14

            Ja, det ligner kunstig intelligens. Jeg foretrækker den ægte vare:-)

            1 Reply Last reply
            0
            • B Offline
              B Offline
              bikube
              wrote on sidst redigeret af
              #15

              1702

              1 Reply Last reply
              0
              • B Offline
                B Offline
                bikube
                wrote on sidst redigeret af
                #16

                aktier til bestyrelsen.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #17

                  Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting / Mim8 https://www.globenewswire.com/news-release/2024/12/03/2990557/0/en/Novo-Nordisk-to-present-new-data-from-sickle-cell-disease-and-haemophilia-trials-at-the-66th-American-Society-of-Hematology-ASH-annual-meeting.html

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #18

                    the GEN1042 trial in combination with radiotherapy / pembrolizumab set to Active, not recruiting - curious if we can get some info on that soonish https://clinicaltrials.gov/study/NCT05491317

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #19

                      the last push upward went from 1515.5 to 1652 = 136.5dkk. This stint went from 1431 to 1567.5 = 136.5dkk. 😉

                      1 Reply Last reply
                      0
                      • T Offline
                        T Offline
                        transalp
                        wrote on sidst redigeret af
                        #20

                        Go morgen.. 🙂

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #21

                          Scancell Announces Genmab Exercises Option to a Second Commercial License Agreement https://www.investegate.co.uk/announcement/rns/scancell-holdings--sclp/second-commercial-license-agreement-with-genmab-/8588688

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #22

                            ‘As bispecific antibodies change DLBCL treatment paradigm, Epkinly draws attention’
                            https://www.koreabiomed.com/news/articleView.html?idxno=25928

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #23

                              Genmab expands its pipeline with $630m Scancell deal https://pharmaphorum.com/news/genmab-expands-its-pipeline-630m-scancell-deal

                              1 Reply Last reply
                              0
                              • DarvinD Offline
                                DarvinD Offline
                                Darvin
                                wrote on sidst redigeret af
                                #24

                                Hej E L og andre. Trist at der er blevet så forholdsvist stille i Genmab chatten. Selv skriver jeg heller ikk som tidligere, men pyt med det. E L - du er mere end guld værd, og ikke kun “værdsat”. Håber virkelig du holder ved. Ligesom Solsen, Bulder og flere andre. Ingen flere nævnt desværre, men heller INGEN glemt. Håber virkelig både Genmab (aktien) og vi andre får gejsten igen. NB! Er selv i den grad fortsat i og omkring Genmab, men trist at positivt afkast kun hentes i spekulative dispositio

                                1 Reply Last reply
                                0
                                • SolsenS Offline
                                  SolsenS Offline
                                  Solsen
                                  wrote on sidst redigeret af
                                  #25

                                  EL er uvurderlig. Vi står overfor ASH og efterfølgende et Genmab event. Så stay tuned.

                                  1 Reply Last reply
                                  0
                                  • DarvinD Offline
                                    DarvinD Offline
                                    Darvin
                                    wrote on sidst redigeret af
                                    #26

                                    Undskyld - den med at ingen var glemt kunne misforståes. Jeg mente naturligvis at der var andre super skribenter end de nævnte. Ville blot ikke remse op. Undskyld hvis det blev tolket anderledes

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #27

                                      we used to keep ourselves busy with news on the royalty pipeline, Dara, amivantamab, teclistamab, talquetamab, kesimpta; there is still plenty of news on those, but the interest has disappeared here. Genmab's own pipeline does not produce that much news yet, data takes a long time.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #28

                                        In hindsight, it would have been better if we had gotten bored of Genmab and become more silent here 2 years ago and sold the lot at 3000... In that light you should even be angry at all the writers for posting too much 😉

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #29

                                          Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy https://www.nature.com/articles/s41408-024-01197-2

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper